Terms: = Lung cancer AND STRN, ENSG00000115808, 6801, O43815, SG2NA, MGC125642 AND Treatment
13 results:
1. Identification of dual strn-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy.
Lin R; Mallick AB; Wang ZX; Brown SA; Lu B; Jiang W
Diagn Pathol; 2023 Oct; 18(1):116. PubMed ID: 37865792
[TBL] [Abstract] [Full Text] [Related]
2.
Bulutay P; Vatansever D; Taskiran C; Mericoz CA; Tokat F; Kapucuoglu N; Kulac I
Indian J Pathol Microbiol; 2023; 66(2):392-395. PubMed ID: 37077094
[TBL] [Abstract] [Full Text] [Related]
3. Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive lung cancers.
Rotow J; Patel JD; Hanley MP; Yu H; Awad M; Goldman JW; Nechushtan H; Scheffler M; Kuo CS; Rajappa S; Harada G; Clifford S; Santucci A; Silva L; Tupper R; Oxnard GR; Kherani J; Drilon A
Clin Cancer Res; 2023 Aug; 29(16):2979-2987. PubMed ID: 36996322
[TBL] [Abstract] [Full Text] [Related]
4. Therapeutic Advances of Rare ALK Fusions in Non-Small Cell lung cancer.
Xiang Y; Zhang S; Fang X; Jiang Y; Fang T; Liu J; Lu K
Curr Oncol; 2022 Oct; 29(10):7816-7831. PubMed ID: 36290895
[TBL] [Abstract] [Full Text] [Related]
5. Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients.
Chen J; Facchinetti F; Braye F; Yurchenko AA; Bigot L; Ponce S; Planchard D; Gazzah A; Nikolaev S; Michiels S; Vasseur D; Lacroix L; Tselikas L; Nobre C; Olaussen KA; Andre F; Scoazec JY; Barlesi F; Soria JC; Loriot Y; Besse B; Friboulet L
Ann Oncol; 2022 Apr; 33(4):434-444. PubMed ID: 35066105
[TBL] [Abstract] [Full Text] [Related]
6. Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations.
Yang X; Zhong J; Yu Z; Zhuo M; Zhang M; Chen R; Xia X; Zhao J
BMC Cancer; 2021 Oct; 21(1):1107. PubMed ID: 34654390
[TBL] [Abstract] [Full Text] [Related]
7. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract] [Full Text] [Related]
8. Coexistence of a secondary strn-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report.
Zeng Q; Gao H; Zhang L; Qin S; Gu Y; Chen Q
Anticancer Drugs; 2021 Sep; 32(8):890-893. PubMed ID: 34232939
[TBL] [Abstract] [Full Text] [Related]
9. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
Zeng H; Liu Y; Wang W; Tang Y; Tian P; Li W
Ann Palliat Med; 2021 Jul; 10(7):8352-8357. PubMed ID: 33832282
[TBL] [Abstract] [Full Text] [Related]
10. Clinical Utility of Cell-Free DNA for the Detection of
McCoach CE; Blakely CM; Banks KC; Levy B; Chue BM; Raymond VM; Le AT; Lee CE; Diaz J; Waqar SN; Purcell WT; Aisner DL; Davies KD; Lanman RB; Shaw AT; Doebele RC
Clin Cancer Res; 2018 Jun; 24(12):2758-2770. PubMed ID: 29599410
[No Abstract] [Full Text] [Related]
11. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.
Hung YP; Dong F; Watkins JC; Nardi V; Bueno R; Dal Cin P; Godleski JJ; Crum CP; Chirieac LR
JAMA Oncol; 2018 Feb; 4(2):235-238. PubMed ID: 28910456
[TBL] [Abstract] [Full Text] [Related]
12. Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.
Yakirevich E; Resnick MB; Mangray S; Wheeler M; Jackson CL; Lombardo KA; Lee J; Kim KM; Gill AJ; Wang K; Gowen K; Sun J; Miller VA; Stephens PJ; Ali SM; Ross JS; Safran H
Clin Cancer Res; 2016 Aug; 22(15):3831-40. PubMed ID: 26933125
[TBL] [Abstract] [Full Text] [Related]
13. Identification of a recurrent strn/ALK fusion in thyroid carcinomas.
Pérot G; Soubeyran I; Ribeiro A; Bonhomme B; Savagner F; Boutet-Bouzamondo N; Hostein I; Bonichon F; Godbert Y; Chibon F
PLoS One; 2014; 9(1):e87170. PubMed ID: 24475247
[TBL] [Abstract] [Full Text] [Related]
